热门资讯> 正文
Xenetic Biosciences报告第二季度业绩
2025-08-13 22:16
- Xenetic Biosciences press release (NASDAQ:XBIO): Q2 Net loss for the quarter ended June 30, 2025 was approximately $0.7 million.
- Research & development expenses for the three months ended June 30, 2025 decreased by approximately $277,000, or 29.7%, to approximately $0.7 million from $0.9 million in the comparable quarter in 2024. General and administrative expenses for the three months ended June 30, 2025 decreased by approximately $472,000, or 41.8%, to approximately $0.7 million from approximately $1.1 million in the comparable quarter in 2024.
More on Xenetic Biosciences
- Seeking Alpha’s Quant Rating on Xenetic Biosciences
- Historical earnings data for Xenetic Biosciences
- Financial information for Xenetic Biosciences
推荐文章
美股机会日报 | 8月非农大幅低于预期！纳指期货短线拉涨约0.7%；特斯拉盘前涨近2%
一周财经日历 | 事关降息！中美5月CPI、PPI重磅出炉！新股“超购王”大行科工下周上市
高盛：降新鸿基地产目标价至96港元 评级“买入”
特朗普白宫宴请硅谷巨头 各大公司CEO纷纷重申在美投资承诺
非农前糟糕就业数据引爆降息预期 10年期美债收益率创四个月新低
AI收入超预期！芯片巨头博通交出满分财报 神秘百亿订单带来惊喜
Lululemon Athletica连续第二次下调全年业绩指引 盘后股价一度暴跌超15%
9月5日外盘头条：马斯克回绝白宫科技CEO晚宴邀请 波音罢工持续无奈招募替代工人 露露柠檬股价盘后暴跌10%
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
